The global drug gap

Science

Volumn 287, Issue 5460, 2000, Pages 1979-1981

  Reich, Michael R ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ANTISCHISTOSOMAL AGENT; ESSENTIAL DRUG; NEW DRUG; PRAZIQUANTEL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MALARIA; PRIORITY JOURNAL; SCHISTOSOMIASIS; SHORT SURVEY; VIRUS INFECTION; WORLD HEALTH ORGANIZATION;

BIOMEDICAL RESEARCH; HEALTH CARE AND PUBLIC HEALTH; INCENTIVES; INTERNATIONAL ASPECTS; JUSTICE;

BIOMEDICAL RESEARCH; CHEMISTRY, PHARMACEUTICAL; DEVELOPING COUNTRIES; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; DRUG THERAPY; DRUG UTILIZATION; DRUGS, ESSENTIAL; HUMANS; INTERNATIONALITY; LEGISLATION, DRUG; PATENTS; PHARMACEUTICAL PREPARATIONS; PRIVATE SECTOR; PUBLIC SECTOR; RESEARCH; WORLD HEALTH;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034678056     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.287.5460.1979     Document Type: Short Survey

References (25)

1. The Use of Essential Drugs (Tenth Model List of Essential Drugs), WHO Technical Reports Series No. 882, Eighth Report of the WHO Expert Committee (WHO, Geneva, 1998).
2. M. R. Reich, Health Policy 8, 39 (1987).
3. World Development Report 1993; Investing in Health (Oxford Univ. Press, New York, 1993).
4. Supply Division Annual Report 1993 (UNICEF, Copenhagen, 1999).
5. Management Sciences for Health, Managing Drug Supply (Kumarian Press with WHO, West Hartford, CT, ed. 2, 1997).
6. B. McPake, K. Hanson, A. Mills, Soc. Sci. Med. 36, 1383 (1993).
7. Guidelines for Drug Donations, revised (WHO, Geneva, 1999).
8. M. R. Reich et al., Bull. WHO 77, 675 (1999).
9. A. S. Fauci, N. Engl. J. Med. 341, 1046 (1999).
10. AIDS Epidemic Update: December 1998 (UNAIDS and WHO, Geneva, 1998).
11. Triple-drug therapy for AIDS requires clinical and Laboratory facilities that are not commonly available in developing countries, especially in sub-Saharan Africa. Even if the drugs were donated free, they could be delivered only to the urban elite who have access to tertiary health care.
12. M. R. Reich, Ed., International Strategies for Tropical Disease Treatments: Experiences with Praziquantel. DAP Research Series No. 26, WHO/DAP/CTD/98.5, Action Programme on Essential Drugs (WHO, Geneva, 1998).
13. E. Parry, Thorax 52, 589 (1997).
14. J. B. Milstien and A. Batson, Drug Inf. J. 32, 175 (1998).
15. M. Kremer, Q. J. Econ. 113, 1137 (1998).
16. P. Bond, Int. J. Health Serv. 29, 765 (1999).
17. T. Fujisaki and M. R. Reich, Assessment of TDR's Contribution to Product Development for Tropical Diseases: The Case of Ivermectin for Onchocerciasis (UNDP/World Bank/WHO Special Programme for Remarch and Training in Tropical Diseases, Geneva, 1997).
18. P. Wehrwein, Harv. Public Health Rev., p. 32 (summer 1999).
19. P. Olliaro, J. Cattani, D. Wirth, JAMA 275, 230 (1996).
20. B. Pécoul, P. Chirac, P. Trouiller, J. Pinel, JAMA 281, 361 (1999).
21. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, Tropical Disease Research, Progress 1975-94. Highlights 1993-94 (TDR Twelfth Programme Report, Geneva, 1995).
22. J. O. Lanjouw, The Introduction of Pharmaceutical Product Patents in India: "Heartless Exploitation of the Poor and Suffering?," Working Paper No. 6366 (National Bureau of Economic Research, Cambridge, MA, 1999).
23. M. Kremer, Purchase Pre-commitments for New Vaccines: Rationale and a Proposed Design, Working Paper (Brookings Institution, Washington, DC, 16 November 1999).
24. P. Trouiller, C. Battistella, J. Pinal, B. Pecoul, Trop. Med. Int. Health 4, 412 (1999).
25. IMS Health (1999), available at www.phrma.org/ publications/industry/profile99/figures99/7-2.html.